ARTICLE | Clinical News
Maxim starting Ceplene Phase II HCV trial
November 1, 2001 8:00 AM UTC
Maxim (MAXM; SSE:MAXM) announced details of its upcoming Phase II Ceplene histamine dihydrochloride trial in patients infected with hepatitis C virus (HCV) who have failed prior therapy. The 280-patie...